Oncolytic viruses are using for the treatment of cancer due to the specific antitumor activity in tumor cells. Herpes simplex virus (HSV) is a human neurogenic dsDNA virus that has the characteristic of life-long latent infection of neurons and allows for long-term transgene expression. Many variants of oncolytic herpes simplex virus have been used for the basic research and clinical trials to apply in various disease areas. Creative Biolabs provides state-of-the-art viral vector construction technology for basic research and preclinical applications.
Partial deletion of the HSV gene results in superior packaging capacity of >30 kb foreign DNA with low toxicity as an expression vector. Multiple modified purified oncolytic herpes simplex virus (oHSV) products can avoid evading the host immune response and reduce toxicity by gene knock-out, such as ICP0, ICP4, ICP22, ICP27 or ICP47. Insertion of various transgene especially cytokines can adapt to clinical diversification needs. Different ways of genomic gene deletion, exogenous gene insertion, capsid modification, miRNA modification, promoter and strains selection are combined to explore oHSV with high oncolytic efficacy and low toxicity for worldwide clients to meet different scientific research demands.
Fig.1 HSV-1 genome
Creative Biolabs utilizes the state-of-the-art viral vector construction technology to provide a series of services, adopt current bioinformatics resources to design and construct HSV vector, provide virus production, purification and quality verification services. Except for the following existing products, we provide customized oncolytic HSV construction services to meet the specific need of our clients. Please feel free to contact us for specific customization details, our scientists will conduct further in-depth discussions on your project and provide comprehensive consultation on the design of oncolytic herpes simplex virus.
Dsred-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP27), CMV-Dsred (Cat#: RepOV-0001XY)
EGFP-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP27), CMV-EGFP (Cat#: RepOV-0002XY)
GFP-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP27), CMV-GFP (Cat#: RepOV-0003XY)
lacZ-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP27), CMV-lacZ (Cat#: RepOV-0004XY)
luciferase-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP27), CMV-luciferase (Cat#: RepOV-0005XY)
mCherry-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP27), CMV-mCherry (Cat#: RepOV-0006XY)
Dsred-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP34.5, ΔUNG), CMV-Dsred (Cat#: RepOV-0007XY)
EGFP-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP34.5, ΔUNG), CMV-EGFP (Cat#: RepOV-0008XY)
GFP-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP34.5, ΔUNG), CMV-GFP (Cat#: RepOV-0009XY)
lacZ-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP34.5, ΔUNG), CMV-lacZ (Cat#: RepOV-0010XY)
luciferase-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP34.5, ΔUNG), CMV-luciferase (Cat#: RepOV-0011XY)
mCherry-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP34.5, ΔUNG), CMV-mCherry (Cat#: RepOV-0012XY)
Dsred-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP6, ΔΔICP34.5), CMV-Dsred (Cat#: RepOV-0013XY)
EGFP-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP6, ΔΔICP34.5), CMV-EGFP (Cat#: RepOV-0014XY)
GFP-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP6, ΔΔICP34.5), CMV-GFP (Cat#: RepOV-0015XY)
lacZ-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP6, ΔΔICP34.5), CMV-lacZ (Cat#: RepOV-0016XY)
luciferase-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP6, ΔΔICP34.5), CMV-luciferase (Cat#: RepOV-0017XY)
mCherry-encoding Oncolytic Herpes Simplex Virus 1 (ΔICP6, ΔΔICP34.5), CMV-mCherry (Cat#: RepOV-0018XY)
Dsred-encoding Oncolytic Herpes Simplex Virus 1 (ΔΔICP0), CMV-Dsred (Cat#: RepOV-0019XY)
EGFP-encoding Oncolytic Herpes Simplex Virus 1 (ΔΔICP0), CMV-EGFP (Cat#: RepOV-0020XY)